Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

929
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
929
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

8.9K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
8.9K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

68
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Analytical and clinical performance of the updated Elecsys Anti-TPO II assay for the detection of antibodies against thyroid peroxidase to aid in the diagnosis of autoimmune thyroid diseases.

Clinical chemistry and laboratory medicine·2026
Same author

Telomere maintaining germline and somatic variants in thyroid cancer and melanoma.

medRxiv : the preprint server for health sciences·2026
Same author

Ectopic Cushing Syndrome due to an Adrenocorticotropic Hormone-Producing Pheochromocytoma.

AACE endocrinology and diabetes·2026
Same author

Comparison of Conventional Smears with Liquid Preparations and Their Combined Use in Thyroid Cytopathology: A Multi-Institutional Study.

Thyroid : official journal of the American Thyroid Association·2026
Same author

Utility of genomic sequencing classifier in managing cytologically indeterminate oncocytic thyroid nodules.

The Journal of clinical endocrinology and metabolism·2026
Same author

Differentiated Thyroid Cancer in Severe Insulin Resistance.

AACE endocrinology and diabetes·2025
Same journal

Stimulating Thyrotropin Receptor Antibodies Enhance the Expression of Both Thyrotropin Receptors and Insulin-Like Growth Factor 1 Receptors in Fibroblasts.

Thyroid : official journal of the American Thyroid Association·2026
Same journal

Mild Thyroid Eye Disease-The Most Common yet the Least Studied Presentation of Thyroid Eye Disease.

Thyroid : official journal of the American Thyroid Association·2026
Same journal

In Memoriam: Lawrence Crane Wood (1935-2026).

Thyroid : official journal of the American Thyroid Association·2026
Same journal

Trends in Management and Outcomes of Pediatric Hyperthyroidism Over Two Decades.

Thyroid : official journal of the American Thyroid Association·2026
Same journal

Targeted Therapy-Induced Erythrocytosis in Thyroid Cancers: An Underrecognized Safety Signal from a Retrospective Study.

Thyroid : official journal of the American Thyroid Association·2026
Same journal

<i>Retraction Notice:</i> High Iodine Concentration Attenuates <i>RET/PTC3</i> Oncogene Activation in Thyroid Follicular Cells.

Thyroid : official journal of the American Thyroid Association·2026
See all related articles

Related Experiment Video

Updated: Mar 29, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.9K

Metformin Attenuates 131I-Induced Decrease in Peripheral Blood Cells in Patients with Differentiated Thyroid Cancer.

Athanasios Bikas1,2, Douglas Van Nostrand3, Kirk Jensen4

  • 11 Division of Endocrinology, Department of Medicine, MedStar Washington Hospital Center , Washington, DC.

Thyroid : Official Journal of the American Thyroid Association
|December 10, 2015
PubMed
Summary
This summary is machine-generated.

Metformin use during radioactive iodine (131I) treatment for differentiated thyroid cancer (DTC) significantly reduced bone-marrow toxicity, particularly in white blood cells (WBC). Patients taking metformin experienced faster blood count recovery compared to controls.

More Related Videos

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.3K
Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

2.4K

Related Experiment Videos

Last Updated: Mar 29, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.9K
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.3K
Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

2.4K

Area of Science:

  • Oncology
  • Pharmacology
  • Hematology

Background:

  • Radioactive iodine (131I) treatment for differentiated thyroid cancer (DTC) can cause hematopoietic toxicity.
  • Metformin, a common diabetes drug, was investigated for potential radioprotective effects on bone marrow function.

Purpose of the Study:

  • To determine if metformin use prevents or mitigates 131I-induced changes in complete blood counts (CBC) in DTC patients.
  • To assess the impact of metformin on white blood cells (WBC), lymphocytes, neutrophils, and platelets post-131I therapy.

Main Methods:

  • Retrospective analysis of CBC values in DTC patients undergoing 131I treatment.
  • Comparison between a group taking metformin (40 patients) and a control group not taking metformin (39 patients).
  • Repeated measures analysis of variance used to analyze CBC changes at baseline and 1, 6, and 12 months post-treatment.

Main Results:

  • Metformin group showed significantly less decrease in WBC counts at 1, 6, and 12 months compared to the control group.
  • While lymphocytes were sensitive to 131I, metformin's radioprotective effect was more pronounced in neutrophils.
  • Platelet reduction was less in the metformin group at 12 months; hemoglobin levels showed no significant difference between groups.

Conclusions:

  • Metformin attenuated 131I-induced decreases in CBC parameters, with notable radioprotective effects on WBC.
  • Patients on metformin exhibited faster recovery of blood counts post-131I therapy.
  • Further research is recommended to explore metformin's radioprotective potential in other cancer therapies.